Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

Record Sales of $490 Million, Up 14 Percent over Third Quarter 2007

Company Raises Full Year 2008 Sales and Earnings Guidance Introduces 2009 Adjusted Net Income Guidance, Up 27 Percent over 2008

FRAZER, Pa., Oct. 28 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today reported third quarter 2008 sales of $489.7 million, compared to sales of $428.7 million for the third quarter of 2007, and at the high end of the company's guidance of $480 - $490 million. Net income for the quarter was $112.0 million and basic income per common share was $1.64. Excluding amortization expense and certain other items, adjusted net income was $92.9 million and basic adjusted income per common share for the quarter was $1.36, compared to $1.08 for the same period in 2007, exceeding the company's guidance of $1.25 to $1.35.

Central nervous system (CNS) franchise sales were $273.7 million during the quarter, a 19 percent increase compared to the same period last year. The Pain franchise sales were $117.2 million compared to $121.8 million in the third quarter of 2007. AMRIX(R) (cyclobenzaprine hydrochloride extended- release capsules) sales increased 20 percent over the second quarter 2008. Oncology franchise sales were $52.4 million, an increase of 131 percent versus 2007. Sales of TREANDA(R) (bendamustine hydrochloride) for Injection were $24.6 million for the quarter, an increase of 71 percent over the second quarter of 2008.

"More and more patients are benefiting from the novel therapies that we offer. This has resulted in record sales, and adjusted earnings that exceeded the high end of our guidance. These solid results, and our confidence in our current product portfolio, enabled us to raise our guidance for the remainder of this year and issue adjusted net income guidance for 2009 that exceeds today's First Call consensus," said Frank Baldino, Jr., Ph.D., Chairman and CEO. "Despite troubled economic conditions around the world, our
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... Industry leader iLab Solutions ... In this newly-created position, Gibbs will lead iLab’s business operations in the region, ... tools. This entails not only introducing iLab to potential partners but support and ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... of California Los Angeles, Boston University School of Medicine, Frederick National Laboratory for ... One, the world’s first multidisciplinary Open Access journal. , Christopher Ryan PhD, ...
(Date:9/1/2015)... 1, 2015 Shire plc (LSE: SHP, ... Mathew to its Board of Directors as a Non-Executive ... Compliance & Risk Committee of the Shire Board. Both appointments ... Sara previously served as Chairman, President and Chief Executive Officer ... During her 12-year tenure at D&B, she helped drive the ...
(Date:8/31/2015)... , Aug. 31, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... $5.7 million. The orders are for air emission abatement projects in ... note is a large order for a municipality in the ... be replacing a competitor,s system that failed to meet the ... engineered solutions," said Derek S. Webb , President and ...
Breaking Biology Technology:iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 2iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 3Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 2Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 3Shire Appoints Sara Mathew to Board of Directors 2
... ... global expert on chemical information, reports that China,s patent office is now ... Japan,s patent office, the World Intellectual Property Organization (WIPO), and the United ... passed the USPTO in 2005, WIPO in 2006, and exceeded Japan for ...
... carbon layer in which the carbon atoms are ... Carbon nanotubes are rolled-up sheets of graphene, and ... boasts some very special characteristics it is ... such conflicting qualities as brittleness and ductility. In ...
... SEATTLE, Nov. 23 Immune Design Corp. (IDC) announced today ... Chairman. Dr. Carter has a successful track record in ... Officer at ZymoGenetics, in Seattle, WA and Chief Scientific Officer ... http://www.newscom.com/cgi-bin/prnh/20091123/SF15228 ) , Dr. Steven Reed, IDC,s founder and Chief ...
Cached Biology Technology:China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 2China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 3Polymer with honeycomb structure 2Immune Design Corp. Announces Appointment of Dr. Bruce L.A. Carter as Executive Chairman and Director 2
(Date:8/19/2015)... HAUPPAUGE, N.Y. , Aug. 19, 2015 /PRNewswire/ ... announced that it has entered into a Definitive ... intellectual property, of iris authentication market leader EyeLock ... transaction, VOXX will have a controlling interest in ... is subject to completion of due diligence.  Expanding ...
(Date:8/12/2015)... 2015   MedNet Solutions , an innovative SaaS-based ... clinical research, is proud to announce that ... eClinical technology platform, has led the way to significant ... of 2015.   Q2 2015 and Q1 2015 were, ... contract value sold in the company,s 15 year history.  ...
(Date:8/11/2015)... Sweden , August 11, 2015 Today, ... FPC1155. Already received as well as expected revenues in 2015 that ... in FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a prominent smartphone manufacturer in ... ZUK selected FPC1 155 for ...
Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5MedNet Solutions Experiences Explosive Corporate Growth 2FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2
... While the iconic Haleakalā silversword plant made a strong recovery ... of substantial climate-related decline. New research published this week warns ... in its native habitat. Known for its striking rosette, ... event at the end of its life, at which time ...
... ornamental fish industry faces a global problem with antibiotic ... for fish diseases may not work when needed ... antibiotic-resistant bacteria. The risk to humans is probably ... compromised immune systems, researchers said, although transmission of disease ...
... University of Texas at Austin have developed a menu of 61 ... of vaccines for diseases such as flu, pertussis, cholera and HPV. ... described in a paper published this month in the journal ... that is poised to transform vaccine design. Adjuvants are substances added ...
Cached Biology News:Global warming may have severe consequences for rare Haleakalā silverswords 2Ornamental fish industry faces increasing problems with antibiotic resistance 2Ornamental fish industry faces increasing problems with antibiotic resistance 3Designer bacteria may lead to better vaccines 2Designer bacteria may lead to better vaccines 3
Vitronectin Immunogen: Purified, full length, native human protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... Guava has made microcapillary flow cytometry accessible ... experts alike will appreciate the latest addition ... Pluseasy to use, surprising affordable, and very ... system includes such features as absolute cell ...
...
Fingerprinting II Basic software is used for analyzing fingerprint sample types (electrophoretic gels, HPLC and other chromatographic patterns, spectrophotometric and densitometric curves)....
Biology Products: